Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD

This article was originally published in The Pink Sheet Daily

Executive Summary

Report from ACC: Experts advise reading the fine print of the study - which failed to show an overall outcome benefit - as sub-group analysis shows highest-risk patients might benefit.

You may also be interested in...



Merck Is Second Big Pharma To Join Optum Labs Research Collaborative

Merck follows Pfizer in signing on to the research collaborative affiliated with insurer UnitedHealth. Research underway or already completed through the collaborative includes a comparison of diabetes drugs and an effort to replicate results of the NIH-sponsored ACCORD trial on cholesterol treatments.

New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials

The cardiology community is increasingly questioning the value of adding on a variety of lipid therapies to treatment with highly effective statins, based on accumulating evidence of the lack of value of affecting cholesterol parameters other than LDL.

Trilipix CV Outcomes Study To Focus On Patients With High Triglycerides, Low HDL-Cholesterol

FDA follows its advisory committee’s recommendation and requires a post-marketing study of Abbott’s fibrate to determine whether combination use with a statin provides a cardiovascular benefit over statin monotherapy in high-risk patients.

Related Content

Topics

UsernamePublicRestriction

Register

PS070342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel